Elicio Therapeutics, Inc. reported its financial results for the year ended December 31, 2024, on March 31, 2025. The company recorded a net loss of $51.9 million for 2024, an increase from $35.2 million in 2023. The net loss per share for 2024 was $4.25, compared to $6.96 for 2023.
Research and development (R&D) expenses for 2024 increased to $33.7 million from $23.8 million in 2023, primarily due to clinical trial expenses associated with the ongoing Phase 2 AMPLIFY-7P study. General and administrative (G&A) expenses decreased slightly to $11.3 million from $11.9 million in the prior year.
As of December 31, 2024, cash and cash equivalents stood at $17.6 million, up from $12.9 million at the end of 2023. Including $10.0 million in gross proceeds from the January 2025 registered direct offering, the company expects its current cash to support operations into the fourth quarter of 2025, extending beyond the anticipated AMPLIFY-7P Phase 2 interim analysis. Elicio also confirmed completion of enrollment in the Phase 2 AMPLIFY-7P study and alignment with the FDA on key elements of the planned ELI-002 Phase 3 study design.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.